Aferrix is an innovative leader in development of novel tools for early diagnosis and monitoring of toxic iron in the serum. The company has developed several methods that quantify different forms of toxic iron in the serum, which are not detected by conventional tests. During 2004 Aferrix will begin providing its iron testing services for treatment centers that specialize in Thalassemia and to pharmaceutical companies that are developing iron chelators.
Aferrix is sourcing its product development and commercialization capabilities from Pronto Diagnostics, a leading provider of molecular diagnostic products with extensive knowledge, experience, and R&D capabilities in SNP-based analysis of genetic variations.
feROSTM LPI is
a new assay for the detection of redox-active Labile Plasma Iron
(LPI). It is significant for the assessment of toxic iron in serum
and for monitoring iron chelation therapy. Product
Info |
|
||||||||||||||||
| feRiskTM DCI is
a novel rapid test for the detection of Directly Chelatable Iron
(DCI) - all DFO accessible iron forms. Product
Info |
|||||||||||||||||
 |
|||||||||||||||||
| feRiskTM NTBI is a test for high-throughput
detection of excessive iron accretion in the circulation, based on
the measurement of Non-Transferrin Bound Iron (NTBI). Product
Info |
|||||||||||||||||
| Aferrix currently offers LPI and DCI testing
services. Please use the following catalog numbers when placing formal orders at order@aferrix.com:
LPI/DCI kit for high-throughput simultaneous detection of LPI
and DCI in sera will be launched in 2005 Support Documents  Labile Plasma Iron: The Need and the Answer Sample collection, handling and shipment instructionsScientific Articles LPI-labile plasma iron in iron overloadProf. Ioav Cabantchik, William Breuer, G. Zanninelli, P. Cianciulli Redox active plasma iron in C282Y/C282Y hemochromatosisCaroline LeLan, Olivier Lore´al, Tally Cohen, Martine Ropert, Hava Glickstein, Fabrice Laine´,Michel Pouchard, Yves Deugnier, Andre´ LeTreut, William Breuer, Z. Ioav Cabantchik and Pierre Brissot Contact Us
Aferrix signed a master services agreement with Novartis Pharmaceuticals Corporation |
|||||||||||||||||
